MedTrace Logo

Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

NCT02341495 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-02-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if by giving a combination of 3 drugs the leukemia will go into complete remission (meaning the leukemia is completely gone), and to find out how long it stays away. The drugs used in this project are FDA approved and commercially available.

Conditions

Interventions

DRUG

Deferasirox

Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO

DRUG

Cholecalciferol

Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO

DRUG

Azacitidine

Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks

Sponsors & Collaborators

  • Elizabeth Henry

    lead OTHER

Principal Investigators

  • Elizabeth Henry, MD · Faculty

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341495 on ClinicalTrials.gov